Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018

  • ID: 4529332
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Countervail Corp
  • Hager Biosciences LLC
  • MORE
Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights:

This latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Countervail Corp
  • Hager Biosciences LLC
  • MORE
Introduction

Report Coverage

Organophosphate and Carbamate Poisoning - Overview

Organophosphate and Carbamate Poisoning - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Organophosphate and Carbamate Poisoning - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development

Countervail Corp

Hager Biosciences LLC

Organophosphate and Carbamate Poisoning - Drug Profiles

AM-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galantamine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PlantVax-1502-H-N - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Butyrylcholinesterase for Organophosphate and Carbamate Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-194B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Organophosphate Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Organophosphate and Carbamate Poisoning - Discontinued Products

Organophosphate and Carbamate Poisoning - Product Development Milestones

Featured News & Press Releases

Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent for Organophosphorus Poisoning awarded

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Universities/Institutes, H1 2018

Table 4: Products under Development by Companies, H1 2018

Table 5: Products under Development by Universities/Institutes, H1 2018

Table 6: Number of Products by Stage and Target, H1 2018

Table 7: Number of Products by Stage and Mechanism of Action, H1 2018

Table 8: Number of Products by Stage and Route of Administration, H1 2018

Table 9: Number of Products by Stage and Molecule Type, H1 2018

Table 10: Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, H1 2018

Table 11: Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences LLC, H1 2018

Table 12: Organophosphate and Carbamate Poisoning - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Targets, H1 2018

Figure 5: Number of Products by Stage and Targets, H1 2018

Figure 6: Number of Products by Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 8: Number of Products by Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Routes of Administration, H1 2018

Figure 10: Number of Products by Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Countervail Corp
  • Hager Biosciences LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll